Navigation Links
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
Date:12/3/2010

es, statistical superiority of NP002 over placebo were observed in a variety of physician- and patient-rated PD efficacy outcome measures relating to dyskinesias.

Abraham Lieberman, MD, the study's principal investigator and Director of the Muhammad Ali Parkinson's Center, commented, "NP002 represents an innovative approach to a common side effect in treating Parkinson's disease and has opened up new ideas on how to approach dyskinesias.  The early study results of NP002 in patients with Parkinson's show promising trends in reducing dyskinesias and in improving gait.  I am encouraged by these results and believe they provide a key piece in understanding and addressing the mechanism of dyskinesias in many of our patients with Parkinson's disease."

J. William Langston, MD, Founder, CEO and Scientific Director of the Parkinson's Institute, stated, "It's impressive that the NP002 study data were encouraging across several scales used to measure dyskinesias.  In particular, the study showed a significant trend in improvement in the objective UDRS scale and statistically significant results on the PGIC scale, which measures how patients feel overall, suggesting an improvement in quality of life.  We are very excited to see this work progress to Phase 2 trials based on these encouraging data."

Carrolee Barlow, MD, PhD, CSO and CMO of BrainCells, Inc., and scientific advisor to Neuraltus on the NP002 program, stated, "Patients with Parkinson's disease currently have no therapeutic options to address the dyskinesias caused by levodopa treatment.  The clinical study demonstrated a clinically important improvement in dyskinesia symptoms that could be detected by both clinicians and patients.  The data are compelling and provide a breakthrough for this condition."

The Phase 1/2 data are the second clinical program results reported by Neuraltus this week, following announcement of clinical results for NP001, which showed
'/>"/>

SOURCE Neuraltus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
3. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
4. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
5. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
6. Onyx Pharmaceuticals Announces December 2010 Investor Events
7. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
8. Prolong Pharmaceuticals Boosts Executive Team
9. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
10. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
11. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... BERKELEY, Calif. and COPENHAGEN, ... CMC Biologics, Inc. , a global leader in clinical ... proteins, announced today that, as part of its global ... of its North American manufacturing facility in ... single-use Bioreactor 6Pack™ facility.  The Bioreactor 6Pack™ configuration consists ...
(Date:6/30/2015)... , June 30, 2015 ... as advisor to Chip-Man Technologies Oy (CMT) on its ... The assets relate to CMTs world leading capabilities in ... the latest in a series of successful global deals ... clients. Fintan Walton , CEO, PharmaVentures, ...
(Date:6/29/2015)... Diagnostics was honored at the 2015 IEEE Spectrum ... Award. IEEE President and CEO, Howard E. Michel , ... award to Principal Scientist Martina Medkova , Ph.D., on ... 2015, at the historic Waldorf Astoria hotel in ... spent more than 3 years as a Daktari scientist developing ...
Breaking Medicine Technology:CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2Daktari Honored with IEEE Spectrum Award 2
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:6/30/2015)... , ... June 30, 2015 , ... ... customers. As a subcontractor, ESSC ranked as one of their top 20 installing ... the last quarter of 2014. Providers are based on timeliness, service, installation, paperwork ...
(Date:6/30/2015)... ... , ... Ticket Down is a reliable source for cheap tickets for Journey at the ... band has been packing venues for years and they are one of the most beloved ... in their career. While Journey is known for their all-around great sound, fans of ...
(Date:6/30/2015)... ... June 30, 2015 , ... The board certified otolaryngologists ... design’ website to inform potential sinus surgery patients about ear, nose, and throat ... information about a wide variety of ENT issues including hearing loss, ear infections, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier this month Wound ... Medicine Course. Clinicians from WCA partnering hospitals across the country, met in Anaheim, ... care and hyperbaric medicine education and training is something that is never complete. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... YouTube video, “Fireside Convalescent Care Center.” The video informs community members of Fireside’s ... continually seeing the need for those seeking care to be well informed and ...
Breaking Medicine News(10 mins):Health News:Electronic Security Specialists (E.S.S.C. Inc) Awarded Top Service Provider Award By Monitronics 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2
... breast cancer patient has to pay thousands of dollars as ... case against the doctor//. Doctor Robert Newton is the family ... case for negligent treatment as they feel that the doctor ... case against Dr. Newton for a compensation of $2million for ...
... seen when Pharma major Wockhardt limited (Thiruvananthapuram) in association with ... vaccine//, marketed the latest vaccine for Hepatitis A. ,Hepatitis ... to be taken to curb the spread of the disease. ... period of almost a month and spreads to humans through ...
... arguments can delay wound healing according to a new study ... New Scientist//. ,.,Researchers at Ohio State University College of ... about half hour daily can have delayed wound healing at ... also cause reduced body immunity. ,42 married couples whose ...
... stabilize the rates of HIV by the year 2020 has ... HIV infected individuals on a monthly basis//. It has also ... below 0.3 percent by 2010. The current projected population of ... recent government decision, poor HIV carriers living in communities are ...
... Her-2/neu positive was helped by her Wangaratta community to ... costs her more than $70,000.// The fund was raised ... could help her to buy Herceptin drug for one ... to chemotherapy and anti-estrogen therapy such as tamoxifen and ...
... novel finding that love and addiction may go hand ... physiological effects manifested as a result of dopamine release// ... than a simulation of the effects observed following drug ... and drug abuse leaves the user with an insatiable ...
Cached Medicine News:Health News:‘Marriage Squabbles’ bad for both Emotional and Physical Wound 2Health News:Love And Drug Addiction Share The Same Chemistry 2
... Dermalinfusion is the only treatment ... a topical dermaceutical while exfoliating ... all skin types and addresses ... conditions including hyperpigmentation, acne, photodamage, ...
... practices that require an increased energy rating ... versatility of the Clareon System enables you ... that would typically require multiple cosmetic lasers. ... obsolescence because the Clareon is specifically designed ...
Disposable. Sterile Suction Tubing....
Bi-phasic peristaltic infusion pump for tumescent work....
Medicine Products: